Trial reportDiabetes, obesity & metabolism2026
Community-Based Personalised Lifestyle Intervention Guided by Intermittent Continuous Glucose Monitoring in Adults With Type 2 Diabetes: A Multicentre Randomised Controlled Trial.
Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsTo evaluate whether a community-based personalised lifestyle intervention guided by intermittent continuous glucose monitoring (CGM) improves glycaemic and cardiometabolic outcomes in adults with type 2 diabetes. MATERIALS AND
methodsIn this multicentre, open-label randomised trial, 180 adults with type 2 diabetes and pre-randomisation HbA1c > 7.0% were assigned 1:1 to the CGM-guided intervention or usual community diabetes management and followed for 12 months. The intervention combined FreeStyle Libre 2 use at baseline, after the Month 3 assessment and at Month 6 with personalised lifestyle guidance and supervised exercise concentrated in the first 3 months. The primary outcome was HbA1c at Month 3, analysed using multiple-imputation ANCOVA adjusted for baseline HbA1c and community site.
resultsThe primary analysis set included 171 participants. The adjusted intervention-minus-control difference in Month 3 HbA1c was -0.09 percentage points (95% CI, -0.38 to 0.21; p = 0.573). Supportive complete-data ANCOVA in 125 participants yielded a similar estimate of -0.12 percentage points (95% CI, -0.44 to 0.20; p = 0.472). No significant between-group HbA1c differences were observed at Months 6 or 12, and secondary outcomes showed no consistent benefit. Two Month 3 responder outcomes nominally favoured the intervention, but neither remained significant after multiplicity adjustment (both q = 0.104). Exploratory analyses identified no baseline subgroup with greater Month 3 benefit.
conclusionsThe intervention did not significantly improve glycaemic or cardiometabolic outcomes beyond usual community care. Whether more sustained feedback and engagement can improve effectiveness requires evaluation before routine implementation.
trial registrationChiCTR2400085258.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.